Supplemental material
Modern Rheumatology
Volume 29, 2019 - Issue 6
Open access
3,099
Views
28
CrossRef citations to date
0
Altmetric
Others
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
David Fitz-PatrickEast-West Medical Research Institute, Honolulu, HI, USA; Correspondence[email protected]
View further author information
, View further author information
Kent RobersonDelta Waves Sleep Disorder & Research Center, Colorado Springs, CO, USA; View further author information
, Kiyoshi NiwaNiwa Family Clinic, Chofu, Tokyo, Japan; View further author information
, Takabumi FujimuraThinkpark Heart Clinic, Tokyo, Japan; View further author information
, Koji MoriMori Clinic, Fukuoka, Japan; View further author information
, Jesse HallArdea Biosciences, Inc., San Diego, CA, USAView further author information
, Xiaohong YanArdea Biosciences, Inc., San Diego, CA, USAView further author information
, Zancong ShenArdea Biosciences, Inc., San Diego, CA, USAView further author information
, Sha LiuArdea Biosciences, Inc., San Diego, CA, USAView further author information
, Yasushi ItoArdea Biosciences, Inc., San Diego, CA, USAView further author information
& Scott BaumgartnerArdea Biosciences, Inc., San Diego, CA, USAView further author information
show all
Pages 1042-1052
|
Received 01 May 2018, Accepted 14 Oct 2018, Published online: 12 Dec 2018
Related Research Data
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
Source:
Dove Press
Was its Withdrawal from the Market in the Best Interest of Patients?
Source:
Springer Science and Business Media LLC
Serum uric acid levels and the risk of flares among gout patients in a US managed care setting
Source:
Informa UK Limited
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Source:
Nature Publishing Group UK
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
Source:
Oxford University Press (OUP)
A Disease Warranting Better Management
Source:
Springer Science and Business Media LLC
Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout
Source:
Wiley
Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout.
Source:
Oxford University Press (OUP)
The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension.
Source:
Informa UK Limited
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.